ELTX Company Profile and Key Details

NASDAQ : ELTX

Elicio Therapeutics

$2.80

-0.11-3.78%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Elicio Therapeutics, Inc. (ELTX) stock declined over -3.78%, trading at $2.80 on NASDAQ, down from the previous close of $2.91. The stock opened at $2.87, fluctuating between $2.75 and $2.90 in the recent session.

Stock Snapshot

2.91

Prev. Close

53.39M

Market Cap

2.745

Day Low

-1.17

P/E Ratio

-2.4

EPS (TTM)

N/A

Cash Flow per Share

2.87

Open

19.07M

Number of Shares

2.895

Day High

41.69%

Free Float in %

N/A

Book Value

405.31K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	2.96	2.96	2.72	2.80	406.91K
Jul 30, 2026	2.92	2.99	2.87	2.91	178.06K
Jul 29, 2026	3.00	3.05	2.80	2.89	259.8K
Jul 28, 2026	2.99	3.09	2.87	2.95	361.41K
Jul 27, 2026	3.08	3.20	2.97	3.00	254.9K
Jul 24, 2026	3.14	3.20	3.00	3.00	247.24K
Jul 23, 2026	3.13	3.22	3.10	3.15	256.97K
Jul 22, 2026	3.08	3.18	2.96	3.12	354K
Jul 21, 2026	3.08	3.16	3.02	3.08	246.04K
Jul 20, 2026	3.13	3.22	3.01	3.04	296.86K
Jul 17, 2026	3.15	3.36	3.10	3.11	755.3K
Jul 16, 2026	3.01	3.28	2.97	3.20	561.09K
Jul 15, 2026	3.15	3.17	2.90	3.04	745.51K
Jul 14, 2026	3.31	3.31	3.07	3.11	771.55K
Jul 13, 2026	3.40	3.48	3.13	3.29	493.13K
Jul 10, 2026	3.50	3.56	3.27	3.48	477.01K
Jul 09, 2026	3.48	3.59	3.32	3.49	1.04M
Jul 08, 2026	2.91	3.67	2.87	3.49	4.17M
Jul 07, 2026	3.30	3.32	2.77	2.80	1.4M
Jul 06, 2026	3.39	3.59	3.25	3.30	1.36M

Contact Details

Boston, MA 02210

United States

https://elicio.com 857 209 0050

About Company

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Company Overview

Elicio Therapeutics, Inc. (NASDAQ:ELTX) closed at $2.80 USD, losing -$0.11 (-3.78%) from the previous close of $2.91. The stock is currently mid-range between its 52-week high and low $2.66 and $16.00. With a market capitalization of about $53.39 million, Elicio Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.78). Key stats such as the average daily volume over the past year has been around 1.69 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Elicio Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert T. Connelly, the company employs approximately 33 people and listed since February 05, 2021. Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases.

Technical Performance

ELTX has shown mixed momentum, gaining 2.71% over the past week and -14.97% over the past quarter, though year-to-date performance is down -0.13%. Short-term trend indicators are mixed aligned (SMA20 33.3%, SMA50 40.47%, SMA200 31.09%). The stock’s 14-day RSI is 77.6 (overbought), while the ATR of 0.75 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.97% below its high and over 155.22% above its low. Average 10-day trading volume of 285.04 thousand shares is below the 3-month average of 1.68 million, indicating normal recent market interest.

Valuation Metrics

Elicio Therapeutics, Inc. trades at a P/E ratio of -1.2, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -35.87 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.4, also above market averages.

Dividend & Fair Value

Elicio Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Elicio Therapeutics, Inc. generated EPS of -$3.40 over the past year. Five-year average earnings growth is 20.96%. Wall Street analysts project EPS growth of 30.94% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $12.00. The high target offers 864.29% upside. The low target suggests 328.57% downside. The mean target is $19.00. This offers 578.57% upside. Elicio Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 32.65%. The prior quarter beat by 4.26%. Over the last six quarters, Apple has recorded several small beats. These include 8.51% in March 31, 2025.

Shareholding & Insider Activity

Elicio Therapeutics, Inc. has 26.26 million shares outstanding. The public float is 12.32 million shares, elevated short interest at 9.20% of float. This equals 1.88 million shares. The short ratio is 0.41 days. Institutional investors hold 25.04% of the float. Insiders own 30.8%.

Financial & Profitability Overview

Over the trailing twelve months, Elicio Therapeutics has not generated any revenue.
On valuation metrics, Elicio Therapeutics trades at a P/E of -1.20, P/S of 0.00 and P/B of -35.87. The current ratio is 2.24 and quick ratio is 2.24. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -343.53 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -9.98, supported by a cash flow-to-debt ratio of -2.68.

Price Forecast & Outlook

Our AI price prediction model suggests that Elicio Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -66.43%, with price expected at $0.94 by August 13, 2026, within a range of $0.00 to $3.96 3-Month Outlook: Projected fall of -32.5%, reaching $1.89 by October 28, 2026, with a range of $1.09 to $2.32. 1-Year Outlook: Projected loss of -77.86%, with price at $0.62 by July 30, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Elicio Therapeutics, Inc. (NASDAQ:ELTX) shares are flat -0.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Elicio Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.60, suggesting 492.86% upside. Our AI forecast model points to short-term weakness (-66.43% over two weeks), a medium-term fall (-32.5% over three months), and a longer-term loss (-77.86% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Elicio Therapeutics, Inc. (ELTX) stock price?

Elicio Therapeutics, Inc. (NASDAQ: ELTX) stock price is $2.80 in the last trading session. During the trading session, ELTX stock reached the peak price of $2.90 while $2.75 was the lowest point it dropped to. The percentage change in ELTX stock occurred in the recent session was -3.78% while the dollar amount for the price change in ELTX stock was - $0.11.

ELTX's industry and sector of operation?

The NASDAQ listed ELTX is part of Biotechnology industry that operates in the broader Healthcare sector. Elicio Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ELTX?

No Data

How ELTX did perform over past 52-week?

ELTX's closing price is 5.26% higher than its 52-week low of $2.66 where as its distance from 52-week high of $16.00 is -82.5%.

How many employees does ELTX have?

Number of ELTX employees currently stands at 33.

Link for ELTX official website?

Official Website of ELTX is: https://elicio.com

How do I contact ELTX?

ELTX could be contacted at phone 857 209 0050 and can also be accessed through its website. ELTX operates from 451 D Street, Boston, MA 02210, United States.

How many shares of ELTX are traded daily?

ELTX stock volume for the day was 405.31K shares. The average number of ELTX shares traded daily for last 3 months was 1.69M.

What is the market cap of ELTX currently?

The market value of ELTX currently stands at $53.39M with its latest stock price at $2.80 and 19.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	33
Beta	1.78
Sales or Revenue	N/A
5Y Sales Change%	-1%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ELTX Company Profile and Key Details

Elicio Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Company Overview

Key Takeaways

Price Forecast & Outlook